SCHEMBL2922804

SCHEMBL2922804

Cc1nc2sc3c(c2c(=O)n1-c1ccccc1)CCC(Br)C3=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
POLB P06746 4/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
BLM P54132 1/20 0.51
GFER P55789 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.41
NPSR1 Q6W5P4 1/20 0.39
HKDC1 Q2TB90 1/20 0.38
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923717 0.80 POLB (0.56) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2924689 0.79 KMT2A (0.46) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2919879 0.75 ALDH1A1 (0.75) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2917209 0.72 ALDH1A1 (0.48) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2925815 0.70 HSD11B1 (0.48) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2925273 0.70 HSD11B1 (0.41) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2920448 0.69 ALDH1A1 (0.48) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2925659 0.68 HSD11B1 (0.62) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL2925516 0.67 MEN1 (0.45) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL12632698 0.65 MAPT (0.52) MAPTMEN1KMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635839-B1 BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY ABBOTT HEALTHCARE PRODUCTS BV (NL) 2010-09-01 EP disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 US disclosed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 MAPT 1642/4885MEN1 2028/4885KMT2A 2945/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 MAPT 1642/4885MEN1 2028/4885KMT2A 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.